A Aforeworn
Forewarned is forearmed.
Home › Niches › Pharmacy & Controlled Substances › Change
Low urgency

FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose

Detected July 27, 2026 · in Pharmacy & Controlled Substances

FDA approved another OTC naloxone nasal spray (Rextovy, 4 mg), expanding access to opioid overdose reversal without a prescription.

Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 27, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. All pharmacies (independent, retail chain, compounding, long-term-care) that stock or dispense naloxone. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline; action recommended within 30 days to align with market availability.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

Another OTC naloxone product (Rextovy) is now available; no prescription needed. Existing OTC naloxone products remain unchanged.

Who it affects

All pharmacies (independent, retail chain, compounding, long-term-care) that stock or dispense naloxone.

What you must do

Review current naloxone inventory and consider adding Rextovy to OTC offerings; update patient education materials to include this new option.

Deadline

No immediate deadline; action recommended within 30 days to align with market availability.

Source: http://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-spray-opioid-overdose

Never miss a change like this again

Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmacy & Controlled Substances